Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
The challenge of undifferentiated sarcomas
Recent studies have improved current understanding of clinical variability and molecular diversity of this subgroup, but many questions remain
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
Change is on the horizon in the management of uveal melanoma
Novel strategies are offering the possibility of extended patient survival and durable disease control
Innovative strategies lead to mixed benefits for rare cancers
Positive findings are presented for advanced Merkel-cell carcinoma plus phaeochromocytoma and paragangliomas, while negative findings are equally important to guide future research
Novel treatment strategies investigated for thymic epithelial tumours lead to uncertain benefits
Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy
Immunotherapy combinations enhance radiotherapy response in resectable sarcoma
Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes